Take this short 5-question quiz to find out what you know--or, what you may have missed--about the latest developments in COPD.
Updated morbidity and mortality numbers, more about asthma–COPD overlap, an FDA drug approval-late 2018 saw a wide range of COPD topics in the medical news. Take this short quiz to find out what you know--or, what you may have missed--about the latest developments in COPD.
1. Which of the results above are being reported in the COPD Foundation’s “COPD in the States Project”?
Answer: D. All of the above. TheCOPD Foundation'sproject finds there is wide variability in COPD prevalence across and within states. In most cases, percentage of smokers in a state aligns with the prevalence of COPD. Notable in the comorbidity analysis is the strong connection to depression and to other common chronic conditions.
Answer: C. Patients with asthma–COPD overlap had worse health status, increased disease burden, and more comorbid conditions than those with COPD or asthma only, according to the study results.
3. Yupelri (revefenacin), FDA approved in November 2018 for maintenance treatment of COPD, is in what drug class?
Answer: C. Long-acting muscarinic antagonists. Revefenacin, the first once-daily, nebulized bronchodilator for the treatment of COPD, has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, revefenacin exhibits pharmacologic effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
4. Which biomarker was recently linked with greater lung function decline, incident spirometry-defined COPD, and incident COPD-related events?
Answer: B. Albuminuria. Chronic lower respiratory diseases (CLRD) are the fourth leading cause of death. Albuminuria, a biomarker of endothelial injury, is associated with lung function decline and incident CLRD. In the current study, associations persisted in participants without current smoking, diabetes, hypertension, or cardiovascular disease
5. The BREATHE Program for patients hospitalized for COPD, which combines transition and long-term self-management support, had what outcomes vs usual care?
Answer: A. Fewer COPD-related hospitalizations and ED visits and better health-related quality of life. The comprehensive 3-month program helped patients and family caregivers with long-term COPD self-management. The mean number of COPD-related acute care events per participant at 6 months was 0.72 and 1.40 in the intervention and usual care groups, respectively. The mean change in HRQoL measured by the St George’s Respiratory Questionnaire total score at 6 months was −1.53 and +5.44 in the intervention and usual care groups.